• Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

Johnson & Johnson

Pharmaceutical giant Johnson & Johnson (JNJ) is one of O’Leary’s top picks. “I love it,” he said in reference to the company, whose products range from a COVID-19 vaccine to Tylenol.

But the stock has disappointed investors in recent years. It’s currently trading at around $155, roughly the same level it was in late 2020. That means investors have had zero capital gains over three years.

The dividend isn’t impressive either. Johnson & Johnson currently offers a 3% dividend yield. That’s lower than the yield on a 30-year U.S. Treasury bill, which has been above 4% as of late.

Nor is the stock cheap. It’s trading at 29 times earnings per share, which is well above the S&P 500 ratio.

For investors seeking wealth creation, there are arguably better options on the market.

Discover How a Simple Decision Today Could Lead to an Extra $1.3 Million in Retirement

Learn how you can set yourself up for a more prosperous future by exploring why so many people who work with financial advisors retire with more wealth.

Discover the full story and see how you could be on the path to an extra $1.3 million in retirement.

Read More

Home Depot

Another O’Leary stock pick is Home Depot Inc. (HD). The home improvement retailer is widely considered a reliable bet for investors. O’Leary likes it because of its size, strong balance sheet and dividends.

However, Home Depot’s dividend yield, at below 3%, is even lower than Johnson & Johnson’s. To put that into context, the U.S. inflation rate is 3.1%, based on the most recent data, which means the dividend isn’t even helping preserve purchasing power for investors.

Home Depot is also forecasting a small dip in revenue and earnings per share this financial year.

On the positive side, the company announced a $15-billion share buyback program in August, which is a bright green flag.

Exxon

Oil and gas giant Exxon Mobil Corp. (XOM) is another stock that O’Leary seems to love. The stock is probably the cheapest one on his list. Exxon currently trades at just around 11 times earnings per share.

And given that the company recently projected a better than two-fold increase in earnings through 2027, the stock may prove a real bargain at its current price.

Exxon offers a 3% dividend yield, but that is enhanced by the company's pledge to increase share buybacks to $20 billion in 2024, from $17 billion in 2023.

Sponsored

Follow These Steps Once Your Portfolio Reaches $100K

If you've amassed a $100k+ portfolio, it's time to meet with a trusted advisor. Zoe Financial's elite network of fiduciary advisors offers personalized strategies to enhance your financial success. Experience exclusive investment opportunities and bespoke wealth management services. Trust Zoe Financial for unparalleled expertise and a commitment to your prosperity.

Vishesh Raisinghani Freelance Writer

Vishesh Raisinghani is a freelance contributor at MoneyWise. He has been writing about financial markets and economics since 2014 - having covered family offices, private equity, real estate, cryptocurrencies, and tech stocks over that period. His work has appeared in Seeking Alpha, Motley Fool Canada, Motley Fool UK, Mergers & Acquisitions, National Post, Financial Post, and Yahoo Canada.

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter. Advertisers are not responsible for the content of this site, including any editorials or reviews that may appear on this site. For complete and current information on any advertiser product, please visit their website.